WWe now have the first real data showing how successful the monkeypox vaccine is in the current outbreak in the United States. On September 28, the US Centers for Disease Control and Prevention (CDC) Spread Preliminary data from 32 US jurisdictions reported monkeypox case rates and vaccination rates with Jynneos, the currently used monkeypox vaccine. By comparing the two, the researchers were able to tentatively determine how effective the vaccine might be, Dr. Rochelle Wallinsky, director of the Centers for Disease Control and Prevention, said during a briefing.
People who received the first dose of the two-dose Jynneos vaccine were at least two weeks less likely to contract monkeypox virus after at least two weeks than those who were not vaccinated.
Genos It was approved in the United States to control smallpox and monkeypox in 2019. Approval for monkeypox was based on data from animal studies, since cases of the disease were not common in the United States at the time. The animal data provided a proxy for how well the shot worked in people, which now appears to be supported by real-world data.
Walinsky said the results “provide a level of cautious optimism that the vaccine is working as intended.” She stressed that the results included people who were two weeks away from their first dose of the two-dose vaccine, and urged people to receive the second dose as recommended – 28 days after the first – in order to benefit from the strongest and most permanent. Protection from infection. However, results indicating protection against infection after the first shot are encouraging.
The findings prompted the CDC to expand the pool of people eligible for Jynneos to include those who may be at high risk of exposure to the virus; They can now use the vaccine as a way to proactively protect themselves. These include partners of people who may be at higher risk of exposure, as well as commercial sex workers. This practice is known as pre-exposure prophylaxis, and represents a shift in the US government’s strategy in controlling the outbreak. Expanding eligibility “will be critical to making sure we continue to provide vaccines for the first and second doses,” Dr. Dimitri Daskalakis, deputy coordinator of the monkeypox response at the White House, said during the briefing. “This means that more people at present or in the future at risk of developing monkeypox are now eligible for the vaccine.”
While the incidence of monkeypox continues to decline—the United States currently has about 200 cases per week, compared to a peak of about 1,000 cases per week in August—due in large part to increased education about the disease and risk factors, as well as a nationwide vaccination program, Officials said. “This is the first look at how well the vaccine works after just one dose,” Walinsky said. “It’s great news, but what we know from the lab data is that the second dose is really important and may provide the lasting protection we need to control the outbreak.”
More must-read stories from TIME